{
    "name": "panitumumab",
    "comment": "Rx",
    "other_names": [
        "Vectibix"
    ],
    "classes": [
        "Antineoplastics",
        "Monoclonal Antibody",
        "Antineoplastics",
        "EGFR Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/vectibix-panitumumab-342261",
    "pregnancy": {
        "common": [
            "Based on data from animal studies and mechanism of action; therapy can cause fetal harm when administered to pregnant women; limited available data on use of therapy in pregnant women are not sufficient to inform a risk of adverse pregnancy-related outcomes; panitumumab is a human IgG monoclonal antibody and may be transferred across the placenta during pregnancy; advise pregnant women of the potential risk to the fetus"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females: Therapy can cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 2 months after last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Females: Based on results from animal fertility studies conducted in female cynomolgus monkeys, therapy may reduce fertility in females of reproductive potential; effects in animal studies were reversible."
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk or effects of panitumumab on breastfed infant or on milk production; human IgG is present in human milk, but published data suggest that breast milk antibodies do not enter neonatal and infant circulation in substantial amounts; because of potential for serious adverse reactions in breastfed infants from therapy, advise women not to breastfeed during treatment and for 2 months after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Dermatologic toxicity",
                    "description": [
                        "Dermatologic toxicities, some severe (NCI-CTC grade 3 or higher), related to panitumumab blockade of EGF binding and subsequent inhibition of EGFR-mediated signaling pathways have been reported in patients receiving panitumumab monotherapy",
                        "Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Increased tumor progression, increased mortality, or lack of benefit in patients with RAS-mutant mCRC; determine RAS-mutant tumor status in an experienced laboratory using an FDA-approved test before treatment",
                "Monitor patients who develop dermatologic toxicities while receiving panitumumab for the development of inflammatory or infectious sequelae; limit sun exposure",
                "Panitumumab is not indicated for use in combination with chemotherapy due to increase in mortality or toxicity",
                "Permanently discontinue in patients developing pulmonary fibrosis/interstitial lung disease",
                "Monitor electrolytes and institute appropriate treatment if needed",
                "Terminate the infusion for severe infusion reactions",
                "Ocular toxicities reported; monitor for keratitis, ulcerative keratitis, or corneal perforation; interrupt or discontinue for acute or worsening keratitis, ulcerative keratitis, or corneal perforation ",
                "Discontinue permanently if patient develops interstitial lung disease, pneumonitis, or lung infiltrates",
                "Avoid pregnancy",
                "Not indicated for treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS (RAS)",
                "Progressively decreasing serum magnesium levels leading to severe (grade 3-4) hypomagnesemia reported; monitor patients for hypomagnesemia and hypocalcemia prior to initiating treatment, periodically during treatment, and for up to 8 weeks after completion of treatment; other electrolyte disturbances, including hypokalemia, have also been observed; replete magnesium and other electrolytes as appropriate"
            ],
            "specific": [
                {
                    "type": "Dermatologic toxicity",
                    "description": [
                        "Clinical manifestations reported include, dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures",
                        "Severe dermatologic toxicities complicated by infection including sepsis, septic death, and abscesses requiring incisions and drainage",
                        "Whether these mucocutaneous adverse reactions were directly related to EGFR inhibition or to idiosyncratic immune-related effects (eg, Stevens Johnson syndrome or toxic epidermal necrolysis) is unclear",
                        "Withhold or discontinue panitumumab and monitor for inflammatory or infectious sequelae in patients with severe dermatologic toxicities"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Erythema",
            "percent": "65"
        },
        {
            "name": "Acneiform dermatitis",
            "percent": "57"
        },
        {
            "name": "Pruritus",
            "percent": "57"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "39"
        },
        {
            "name": "Fatigue",
            "percent": "26"
        },
        {
            "name": "Abdominal pain",
            "percent": "25"
        },
        {
            "name": "Paronychia",
            "percent": "25"
        },
        {
            "name": "Skin exfoliation",
            "percent": "25"
        },
        {
            "name": "Nausea",
            "percent": "23"
        },
        {
            "name": "Rash",
            "percent": "22"
        },
        {
            "name": "Constipation",
            "percent": "21"
        },
        {
            "name": "Diarrhea",
            "percent": "21"
        },
        {
            "name": "Vomiting",
            "percent": "21"
        },
        {
            "name": "Skin fissures",
            "percent": "20"
        },
        {
            "name": "Cough",
            "percent": "14"
        },
        {
            "name": "Dermatologic toxicity",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "14"
        },
        {
            "name": "Acne",
            "percent": "13"
        },
        {
            "name": "Peripheral edema",
            "percent": "12"
        },
        {
            "name": "Abdominal pain",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "7"
        },
        {
            "name": "Pulmonary embolism",
            "percent": "3"
        },
        {
            "name": "Grades",
            "percent": "5"
        },
        {
            "name": "to",
            "percent": "7"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "4"
        },
        {
            "name": "Angioedema",
            "percent": "3"
        },
        {
            "name": "All grades",
            "percent": "4"
        },
        {
            "name": "to",
            "percent": "3"
        },
        {
            "name": "Complication of infusion",
            "percent": "4"
        },
        {
            "name": "All grades",
            "percent": "3"
        },
        {
            "name": "to",
            "percent": "4"
        },
        {
            "name": "Constipation",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "0.4-3.8"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Binding antibodies",
            "percent": "4"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "and",
            "percent": "4"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "and",
            "percent": "4"
        },
        {
            "name": "Nausea",
            "percent": "1"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "Anaphylaxis",
            "percent": "4"
        },
        {
            "name": "Complication of infusion",
            "percent": "1"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "and",
            "percent": null
        },
        {
            "name": "Sepsis",
            "percent": null
        },
        {
            "name": "Pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Growth of eyelashes",
            "percent": null
        },
        {
            "name": "Increased tears",
            "percent": null
        },
        {
            "name": "Ocular hyperemia",
            "percent": null
        },
        {
            "name": "Mucositis",
            "percent": null
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Skin necrosis",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylactoid reaction",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Keratitis",
            "percent": null
        },
        {
            "name": "ulcerative keratitis",
            "percent": null
        },
        {
            "name": "corneal perforation",
            "percent": null
        },
        {
            "name": "Life threatening and fatal bullous mucocutaneous disease",
            "percent": null
        }
    ]
}